Disease relevance of 5-Fluoropyrimidine

• These results are discussed in the context of similar consequences of 5-fluoropyrimidine toxicity and pyrimidine catabolism mutations in humans [1].

High impact information on 5-Fluoropyrimidine

• The synergy, observed in vitro and probably in vivo, was linked to a trimetrexate-induced elevation of intracellular PRPP, thus facilitating the production of 5-fluoropyrimidine nucleotides [2].
• The possible role of Tyr-33 in 5-fluoropyrimidine-mediated inhibition of TS is discussed [3].
• It was hypothesized that this activity was mediated through synthesis of 5-fluoro-2'-deoxyuridylate, an inactivator of thymidylate synthase, or through incorporation of 5-fluoropyrimidine residues into nucleic acids [4].
• PURPOSE: Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme of 5-fluoropyrimidine (5-FU) catabolism [5].
• The possible role of Tyr-33 in 5-fluoropyrimidine-mediated inhibition of TS is discussed [6].

Chemical compound and disease context of 5-Fluoropyrimidine

• Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells [7].

Associations of 5-Fluoropyrimidine with other chemical compounds

• A radiochemical assay for thymidylate synthase (EC 2.1.1.45, dTMP synthase), which permits the accurate determination of total, free, and 5-fluoro-2'-deoxyuridylate (FdUMP)-bound enzyme in cells exposed to the 5-fluoropyrimidine anticancer agents, is described [8].

References